Skip to main content

Advertisement

Log in

Recognizing and Managing Left Ventricular Dysfunction Associated With Therapeutic Inhibition of the Vascular Endothelial Growth Factor Signaling Pathway

  • Cardio-oncology (S Francis, Section Editor)
  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Opinion statement

Therapeutic inhibition of the vascular endothelial growth factor (VEGF) signaling pathway (VSP) is increasingly employed in the contemporary treatment of many cancer types. VSP inhibitors include the anti-VEGF monoclonal antibody (bevacizumab), soluble VEGF receptors (VEGF Trap), and small molecule tyrosine kinase inhibitors (TKIs) targeting the intracellular kinase domain of VEGF receptors. These agents are associated with cardiovascular toxicities such as hypertension, thrombosis, myocardial ischemia, and left ventricular (LV) dysfunction. Data on VSP inhibitor-associated LV dysfunction are largely limited to retrospective studies. Prospective studies are needed to establish the clinical significance of VSP inhibitor-associated LV dysfunction in the general population. Pre-clinical models of VSP inhibitor-associated LV dysfunction have identified mechanisms of cardiotoxicity and may improve our understanding of the pathophysiology underlying other cardiomyopathies. This review provides an overview of LV dysfunction that can occur in patients treated with VSP inhibitors. Potential strategies for clinical detection and management of this cardiotoxicity are explored, while acknowledging that currently available data specific to VSP-inhibitor LV dysfunction are limited. Avenues for future research are suggested.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: •Of importance

  1. Choueiri TK, Mayer EL, Je Y, Rosenberg JE, Nguyen PL, Azzi GR, et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(6):632–8. doi:10.1200/JCO.2010.31.9129.

    Article  CAS  Google Scholar 

  2. Tsai HT, Marshall JL, Weiss SR, Huang CY, Warren JL, Freedman AN, et al. Bevacizumab use and risk of cardiovascular adverse events among elderly patients with colorectal cancer receiving chemotherapy: a population-based study. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2013;24(6):1574–9. doi:10.1093/annonc/mdt019.

    Article  Google Scholar 

  3. Ramlau R, Gorbunova V, Ciuleanu TE, Novello S, Ozguroglu M, Goksel T, et al. Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(29):3640–7. doi:10.1200/JCO.2012.42.6932.

    Article  CAS  Google Scholar 

  4. Chen H, Modiano MR, Neal JW, Brahmer JR, Rigas JR, Jotte RM, et al. A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer. Br J Cancer. 2013. doi:10.1038/bjc.2013.735.

    Google Scholar 

  5. Richards CJ, Je Y, Schutz FA, Heng DY, Dallabrida SM, Moslehi JJ, et al. Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(25):3450–6. doi:10.1200/JCO.2010.34.4309.

    Article  CAS  Google Scholar 

  6. Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722–31. doi:10.1056/NEJMoa1303989. This is an important clinical trial comparing pazopanib and suntinib for the treatment of metastatic renal cell carcinoma where study design did include prospective surveillance of LVEF in a subset of patients.

    Article  CAS  PubMed  Google Scholar 

  7. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370(9604):2011–9. doi:10.1016/S0140-6736(07)61865-0.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(32):5204–12. doi:10.1200/JCO.2007.15.6331.

    Article  Google Scholar 

  9. Khakoo AY, Kassiotis CM, Tannir N, Plana JC, Halushka M, Bickford C, et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer. 2008;112(11):2500–8. doi:10.1002/cncr.23460.

    Article  CAS  PubMed  Google Scholar 

  10. Telli ML, Witteles RM, Fisher GA, Srinivas S. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2008;19(9):1613–8. doi:10.1093/annonc/mdn168.

    Article  CAS  Google Scholar 

  11. Di Lorenzo G, Autorino R, Bruni G, Carteni G, Ricevuto E, Tudini M, et al. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2009;20(9):1535–42. doi:10.1093/annonc/mdp025.

    Article  Google Scholar 

  12. Brander D, Rizzieri D, Gockerman J, Diehl L, Shea TC, Decastro C, et al. Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma. Leuk Lymphoma. 2013;54(12):2627–30. doi:10.3109/10428194.2013.784969.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(27):4462–8. doi:10.1200/JCO.2008.21.7034.

    Article  CAS  Google Scholar 

  14. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303–12. doi:10.1016/S0140-6736(12)61900-X.

    Article  CAS  PubMed  Google Scholar 

  15. Gupta R, Maitland ML. Sunitinib, hypertension, and heart failure: a model for kinase inhibitor-mediated cardiotoxicity. Curr Hypertens Rep. 2011;13(6):430–5. doi:10.1007/s11906-011-0229-4.

    Article  CAS  PubMed  Google Scholar 

  16. Groarke JD, Cheng S, Moslehi J. Cancer-drug discovery and cardiovascular surveillance. N Engl J Med. 2013;369(19):1779–81. doi:10.1056/NEJMp1313140.

    Article  CAS  PubMed  Google Scholar 

  17. Wu CF, Chuang WP, Li AH, Hsiao CH. Cardiac magnetic resonance imaging in sunitinib malate-related cardiomyopathy: no late gadolinium enhancement. J Chin Med Assoc JCMA. 2009;72(6):323–7. doi:10.1016/S1726-4901(09)70379-X.

    Article  Google Scholar 

  18. Toubert ME, Vercellino L, Faugeron I, Lussato D, Hindie E, Bousquet G. Fatal heart failure after a 26-month combination of tyrosine kinase inhibitors in a papillary thyroid cancer. Thyroid Off J Am Thyroid Assoc. 2011;21(4):451–4. doi:10.1089/thy.2010.0270.

    Article  CAS  Google Scholar 

  19. Abe K, Toba M, Alzoubi A, Ito M, Fagan KA, Cool CD, et al. Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. Circulation. 2010;121(25):2747–54. doi:10.1161/CIRCULATIONAHA.109.927681.

    Article  PubMed  Google Scholar 

  20. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults a Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009;53(15):e1–90. doi:10.1016/j.jacc.2008.11.013.

    Article  PubMed  Google Scholar 

  21. May D, Gilon D, Djonov V, Itin A, Lazarus A, Gordon O, et al. Transgenic system for conditional induction and rescue of chronic myocardial hibernation provides insights into genomic programs of hibernation. Proc Natl Acad Sci U S A. 2008;105(1):282–7. doi:10.1073/pnas.0707778105.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. Chintalgattu V, Ai D, Langley RR, Zhang J, Bankson JA, Shih TL, et al. Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress. J Clin Invest. 2010;120(2):472–84. doi:10.1172/JCI39434.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Chintalgattu V, Rees ML, Culver JC, Goel A, Jiffar T, Zhang J, et al. Coronary microvascular pericytes are the cellular target of sunitinib malate-induced cardiotoxicity. Sci Transl Med. 2013;5(187):187ra69. doi:10.1126/scitranslmed.3005066. This important study provides mechanistic insights into sunitinib malate-induced cardiotoxicity.

    Article  PubMed  Google Scholar 

  24. Moslehi J, Minamishima YA, Shi J, Neuberg D, Charytan DM, Padera RF, et al. Loss of hypoxia-inducible factor prolyl hydroxylase activity in cardiomyocytes phenocopies ischemic cardiomyopathy. Circulation. 2010;122(10):1004–16. doi:10.1161/CIRCULATIONAHA.109.922427.

    Article  CAS  PubMed  Google Scholar 

  25. Bekeredjian R, Walton CB, MacCannell KA, Ecker J, Kruse F, Outten JT, et al. Conditional HIF-1alpha expression produces a reversible cardiomyopathy. PLoS One. 2010;5(7):e11693. doi:10.1371/journal.pone.0011693.

    Article  PubMed Central  PubMed  Google Scholar 

  26. Uraizee I, Cheng S, Moslehi J. Reversible cardiomyopathy associated with sunitinib and sorafenib. N Engl J Med. 2011;365(17):1649–50. doi:10.1056/NEJMc1108849.

    Article  CAS  PubMed  Google Scholar 

  27. Kerkela R, Woulfe KC, Durand JB, Vagnozzi R, Kramer D, Chu TF, et al. Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clin Transl Sci. 2009;2(1):15–25. doi:10.1111/j.1752-8062.2008.00090.x.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  28. Staehler M, Haseke N, Zilinberg K, Stadler T, Stief CG. Plasma N-terminal pro-brain natriuretic peptide as prognostic marker in fatal cardial decompensation with sunitinib malate therapy. Urol Int. 2010;84(1):119–21. doi:10.1159/000273480.

    Article  PubMed  Google Scholar 

  29. Lipshultz SE, Miller TL, Scully RE, Lipsitz SR, Rifai N, Silverman LB, et al. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(10):1042–9. doi:10.1200/JCO.2010.30.3404.

    Article  CAS  Google Scholar 

  30. Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging. 2012;5(5):596–603. doi:10.1161/CIRCIMAGING.112.973321.

    Article  PubMed Central  PubMed  Google Scholar 

  31. Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004;109(22):2749–54. doi:10.1161/01.CIR.0000130926.51766.CC.

    Article  CAS  PubMed  Google Scholar 

  32. Cardinale D, Sandri MT, Martinoni A, Borghini E, Civelli M, Lamantia G, et al. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2002;13(5):710–5.

    Article  CAS  Google Scholar 

  33. Dolci A, Dominici R, Cardinale D, Sandri MT, Panteghini M. Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: systematic review of the literature and recommendations for use. Am J Clin Pathol. 2008;130(5):688–95. doi:10.1309/AJCPB66LRIIVMQDR.

    Article  CAS  PubMed  Google Scholar 

  34. Steingart RM, Bakris GL, Chen HX, Chen M-H, Force T, Ivy SP, et al. Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors. Am Heart J. 2012;163(2):156–63. doi:10.1016/j.ahj.2011.10.018.

    Article  CAS  PubMed  Google Scholar 

  35. Altena R, Perik PJ, van Veldhuisen DJ, de Vries EG, Gietema JA. Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol. 2009;10(4):391–9. doi:10.1016/S1470-2045(09)70042-7.

    Article  CAS  PubMed  Google Scholar 

  36. Sawaya H, Plana JC, Scherrer-Crosbie M. Newest echocardiographic techniques for the detection of cardiotoxicity and heart failure during chemotherapy. Heart Fail Clin. 2011;7(3):313–21. doi:10.1016/j.hfc.2011.03.003.

    Article  PubMed  Google Scholar 

  37. Thavendiranathan P, Grant AD, Negishi T, Plana JC, Popovic ZB, Marwick TH. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J Am Coll Cardiol. 2013;61(1):77–84. doi:10.1016/j.jacc.2012.09.035.

    Article  PubMed  Google Scholar 

  38. Tassan-Mangina S, Codorean D, Metivier M, Costa B, Himberlin C, Jouannaud C, et al. Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective study. Eur J echocardiogr J Work Group Echocardiogr Eur Soc Cardiol. 2006;7(2):141–6. doi:10.1016/j.euje.2005.04.009.

    Article  Google Scholar 

  39. Radulescu D, Pripon S, Parv A, Duncea C, Ciuleanu TE, Radulescu LI. Altered left ventricular diastolic performance in oncologic patients treated with epirubicin. Congestive Heart Fail. 2007;13(4):215–20. doi:10.1111/j.1527-5299.2007.07122.x.

    Article  CAS  Google Scholar 

  40. Pudil R, Horacek JM, Strasova A, Jebavy L, Vojacek J. Monitoring of the very early changes of left ventricular diastolic function in patients with acute leukemia treated with anthracyclines. Exp Oncol. 2008;30(2):160–2.

    CAS  PubMed  Google Scholar 

  41. Mornos C, Petrescu L. Early detection of anthracycline-mediated cardiotoxicity: the value of considering both global longitudinal left ventricular strain and twist. Can J Physiol Pharmacol. 2013;91(8):601–7. doi:10.1139/cjpp-2012-0398.

    Article  CAS  PubMed  Google Scholar 

  42. Negishi K, Negishi T, Hare JL, Haluska BA, Plana JC, Marwick TH. Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr. 2013;26(5):493–8. doi:10.1016/j.echo.2013.02.008.

    Article  Google Scholar 

  43. Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Cohen V, et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol. 2011;107(9):1375–80. doi:10.1016/j.amjcard.2011.01.006.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  44. Ylanen K, Poutanen T, Savikurki-Heikkila P, Rinta-Kiikka I, Eerola A, Vettenranta K. Cardiac magnetic resonance imaging in the evaluation of the late effects of anthracyclines among long-term survivors of childhood cancer. J Am Coll Cardiol. 2013;61(14):1539–47. doi:10.1016/j.jacc.2013.01.019.

    Article  PubMed  Google Scholar 

  45. Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. J Am Coll Cardiol. 2007;50(19):1914–31. doi:10.1016/j.jacc.2007.09.008.

    Article  PubMed  Google Scholar 

  46. Seicean S, Seicean A, Alan N, Plana JC, Budd GT, Marwick TH. Cardioprotective effect of beta-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure. Circ Heart Fail. 2013;6(3):420–6. doi:10.1161/CIRCHEARTFAILURE.112.000055.

    Article  CAS  PubMed  Google Scholar 

  47. Seicean S, Seicean A, Plana JC, Budd GT, Marwick TH. Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study. J Am Coll Cardiol. 2012;60(23):2384–90. doi:10.1016/j.jacc.2012.07.067.

    Article  CAS  PubMed  Google Scholar 

  48. Porta C, Paglino C, Imarisio I, Bonomi L. Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin Exp Med. 2007;7(4):127–34. doi:10.1007/s10238-007-0145-8.

    Article  CAS  PubMed  Google Scholar 

  49. Jones SP, Teshima Y, Akao M, Marban E. Simvastatin attenuates oxidant-induced mitochondrial dysfunction in cardiac myocytes. Circ Res. 2003;93(8):697–9. doi:10.1161/01.RES.0000097262.21507.DF.

    Article  CAS  PubMed  Google Scholar 

  50. Carreira RS, Monteiro P, Gon Alves LM, Providencia LA. Carvedilol: just another Beta-blocker or a powerful cardioprotector? Cardiovasc Hematol Disord Drug Targets. 2006;6(4):257–66.

    Article  CAS  PubMed  Google Scholar 

  51. Bamias A, Lainakis G, Manios E, Koroboki E, Karadimou A, Zakopoulos N, et al. Could rigorous diagnosis and management of hypertension reduce cardiac events in patients with renal cell carcinoma treated with tyrosine kinase inhibitors? J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(15):2567–9. doi:10.1200/JCO.2008.21.6028. author reply 9-70.

    Article  Google Scholar 

  52. Izzedine H, Ederhy S, Goldwasser F, Soria JC, Milano G, Cohen A, et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2009;20(5):807–15. doi:10.1093/annonc/mdn713.

    Article  CAS  Google Scholar 

  53. Disel U, Abali H, Sumbul AT, Ozyilkan O. Hypertension associated with angiogoenesis inhibitors: what do oncologists really do in daily routine? A small survey. J Clin Hypertens. 2011;13(11):863. doi:10.1111/j.1751-7176.2011.00526.x.

    Article  Google Scholar 

  54. Copur MS, Obermiller A. An algorithm for the management of hypertension in the setting of vascular endothelial growth factor signaling inhibition. Clin Colorectal Cancer. 2011;10(3):151–6. doi:10.1016/j.clcc.2011.03.021.

    Article  CAS  PubMed  Google Scholar 

  55. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA J Am Med Assoc. 2013. doi:10.1001/jama.2013.284427.

    Google Scholar 

  56. Langenberg MH, van Herpen CM, De Bono J, Schellens JH, Unger C, Hoekman K, et al. Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(36):6152–9. doi:10.1200/JCO.2009.22.2273.

    Article  CAS  Google Scholar 

  57. Hutson TE, Figlin RA, Kuhn JG, Motzer RJ. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist. 2008;13(10):1084–96. doi:10.1634/theoncologist.2008-0120.

    Article  CAS  PubMed  Google Scholar 

  58. La Vine DB, Coleman TA, Davis CH, Carbonell CE, Davis WB. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma. Am J Clin Oncol. 2010;33(3):217–20. doi:10.1097/COC.0b013e3181a650a6.

    PubMed  Google Scholar 

  59. Wong MK, Jarkowski A. Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature. Pharmacotherapy. 2009;29(4):473–8. doi:10.1592/phco.29.4.473.

    Article  CAS  PubMed  Google Scholar 

  60. Negishi K, Negishi T, Haluska BA, Hare JL, Plana JC, Marwick TH. Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection. Eur Heart J Cardiovasc Imaging. 2013. doi:10.1093/ehjci/jet159.

    PubMed  Google Scholar 

  61. Colombo A, Meroni CA, Cipolla CM, Cardinale D. Managing cardiotoxicity of chemotherapy. Curr Treat Options Cardiovasc Med. 2013;15(4):410–24. doi:10.1007/s11936-013-0248-3.

    Article  PubMed  Google Scholar 

  62. Hawkes EA, Okines AF, Plummer C, Cunningham D. Cardiotoxicity in patients treated with bevacizumab is potentially reversible. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(18):e560–2. doi:10.1200/JCO.2011.35.5008.

    Article  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Dr. John D. Groarke, Dr. David Slosky, Dr. Susan Cheng, and Dr. Javid Moslehi each declare no potential conflicts of interest.

Dr. Toni K. Choueiri has received research funding from Pfizer and is on the advisory board for Pfizer, Glaxosmithkline, Aveo and Novartis pharmaceutical companies.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Javid Moslehi MD.

Additional information

This article is part of the Topical Collection on Cardio-oncology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Groarke, J.D., Choueiri, T.K., Slosky, D. et al. Recognizing and Managing Left Ventricular Dysfunction Associated With Therapeutic Inhibition of the Vascular Endothelial Growth Factor Signaling Pathway. Curr Treat Options Cardio Med 16, 335 (2014). https://doi.org/10.1007/s11936-014-0335-0

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11936-014-0335-0

Keywords

Navigation